Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Up 298.4% in December

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 494,378 shares, an increase of 298.4% from the November 30th total of 124,098 shares. Approximately 80.0% of the company’s shares are sold short. Based on an average daily trading volume, of 3,356,723 shares, the short-interest ratio is presently 0.1 days. Based on an average daily trading volume, of 3,356,723 shares, the short-interest ratio is presently 0.1 days. Approximately 80.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

NASDAQ BDRX opened at $2.86 on Thursday. Biodexa Pharmaceuticals has a fifty-two week low of $2.83 and a fifty-two week high of $92.00. The business has a 50 day moving average price of $5.45 and a two-hundred day moving average price of $6.93.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.